ABSTRACT-The effects of SM-9018, a potential atypical neuroleptic, on monoamine metabolism were studied in rats. SM-9018 dose-dependently increased the levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the cerebral cortex and striatum without affecting the levels of 5-HT, norepinephrine and their metabolites. This action persisted for 8 hr with a maximum effect at 1-2 hr. The SM-9018-induced increase of dopamine (DA) turnover, as indexed by HVA/DA and DOPAC/DA ratios, was comparable in the cerebral cortex and striatum, whereas the typical neuroleptic haloperidol preferential ly enhanced the striatal DA turnover. These findings suggest that SM-9018, unlike haloperidol, increases DA turnover to a similar extent both in the cerebral cortex and striatum.
It is well documented that dopamine (DA) D2 blocking activities of neuroleptics correlate well with their clinical efficacy against schizophrenia (1) . However, most neuro leptics are only effective for the positive symptoms of schizophrenia (e.g., hallucination and delusion), but not for the negative symptoms (e.g., apathy, social withdraw al and flattening affection) (2) . In addition, they often produce severe extrapyramidal side-effects (EPS) such as akathisia, parkinsonism and tardive dyskinesia during the treatment. Recent clinical studies (3 5) have shown that the blockade of central 5-HT2 receptors provides ben eficial effects in the treatment of schizophrenia, such as 1) amelioration of the negative symptoms, 2) reduction of EPS associated with typical neuroleptic treatment and 3) improvement of sleep quality.
SM-9018 (cis-2-(4-(4-(1,2-benzoisothiazol-3-yl)-1-piper azinyl)butyl)hexahydro-lH-isoindole-1,3(2H)-dione HCI) is a novel neuroleptic candidate that has combined 5-HT2 and D2 blocking actions. The compound exhibits high affinities for both 5-HT2 and D2 receptors (K, value= 0.61 and 1.4 nM, respectively) and potently blocks various be haviors mediated by these receptors (6, 7) . In addition, SM-9018 is much weaker than the typical neuroleptics, haloperidol and chlorpromazine, in inducing catalepsy in rodents (6) . Therefore, SM-9018 seems likely to be one of the so-called atypical neuroleptics (e.g., clozapine, thioridazine and sulpiride), which are characterized by a low incidence of EPS in humans. In the present study, we studied the effects of SM-9018 on monoamine metabolism in rats using ex vivo measurement methods and compared its effects to those of haloperidol.
Male Sprague-Dawley rats (Japan SLC, Inc., Shizu oka), each weighing 200-230 g, were used. On the day of the experiments, the animals were killed by decapitation after oral administration of drugs or vehicle (control). The brain was rapidly removed, chilled in ice-cold saline and dissected into eight brain regions: cerebral cortex, striatum, hippocampus, thalamus, hypothalamus, mes encephalon, pons-medulla oblongata and cerebellum. The rostroventral part of the striatum (approximately a 2-mm block) containing the nucleus accumbens was re moved to reduce its influence on striatal monoamine metabolism. The tissues were then frozen in ethanol-dry ice and stored at -70C until the analysis.
Monoamines and their metabolites were analyzed using high performance liquid chromatography with electro chemical detection (HPLC-ECD), as described previously (8) . Briefly, the brain tissues were homogenized in 5 9 volumes of ice-cold 0.1 N perchloric acid containing 5 mM EDTA 2 Na and isoproterenol (internal standard). After centrifugation at 10,000 x g for 30 min at 41C, ali quots of the supernatant were applied to the HPLC-ECD system. For determination of the total 3-methyl-4-hydroxy phenylethyleneglycol (MOPEG) level, a sulfate conjugat ed form of MOPEG (MOPEG-SO4) was hydrolyzed with sulfatase, and then applied to the HPLC-ECD system. SM-9018 and haloperidol were synthesized at Sumi tomo Pharmaceuticals Co., Ltd. Other drugs used in this study were as follows: 3,4-dihydroxyphenylacetic acid SM-9018 and haloperidol were suspended in 0.5% methyl cellulose solution and orally administered at a volume of 5 ml/kg body weight. Control animals were given an equivalent volume of vehicle alone. Student's t-test was used only for comparisons between the two groups. Statistical significance in the DA turnover ratios between the cortex and striatum was determined by two-way ANOVA followed by Williams' multiple com parison test.
The levels of DA, 5-HT, NE and their metabolites in the various brain regions were measured 1 hr after oral ad ministration of SM-9018 at 10 mg/kg. This dose of SM 9018 was sufficient to block both 5-HT2 and D2 receptors in various behavioral tests (6) . As shown in Table 1 , SM 9018 significantly (P<0.01) increased the level of DA metabolites, DOPAC and HVA, in the cerebral cortex and striatum, but not in other brain regions, i.e., hip pocampus, hypothalamus, thalamus, mesencephalon, pons-medulla oblongata and cerebellum. DOPAC and HVA contents in the cerebral cortex and striatum in creased 2 to 2.5-fold in rats treated with SM-9018 as com pared to those in control rats. Slight (but not significant) increases in DOPAC and HVA levels were also observed in the hypothalamus, thalamus and mesencephalon. No significant change in DA level was found in any brain region examined. In addition, SM-9018 did not significant ly change the level of 5-HT, NE or their metabolites (i.e., 5-HIAA and MOPEG, respectively) in any brain region examined. Figure 1 shows the time-course of the effects of SM 9018 on DA turnover, as indexed by HVA/DA and DOPAC/DA ratios. SM-9018 at 10 mg/kg (p.o.) rapidly increased the DA turnover in the cerebral cortex and stria tum. The HVA/DA and DOPAC/DA ratios in both brain regions reached to about 400 and 250-300% of the control level, respectively, within 1 2 hr, and these effects persisted up to 8 hr.
We next compared the effects of SM-9018 on DA turn over with those of a typical neuroleptic haloperidol. As shown in Fig. 2 , orally administered SM-9018 at 0.3 30 mg/kg dose-dependently increased HVA/DA and DOPAC/DA ratios in the cerebral cortex and striatum. The dose-response curves for the increase of HVA/DA and DOPAC/DA ratios by SM-9018 were practically com parable in the two areas, and the ratios were about 400% and 350010 of the control level, respectively, at 30 mg/kg ( Fig. 2A) . Haloperidol at 0.1-10 mg/kg (p.o.) also in creased the HVA/DA and DOPAC/DA ratio in a dose Table 1 . Effects of SM-9018 on norepinephrine (NE), dopamine (DA), 5-HT and their metabolite levels in various regions of the rat brain dependent manner (Fig. 2B) . However, the extent of haloperidol-induced DA turnover in the striatum was sig nificantly higher (by two-way ANOVA) than that in the cerebral cortex. Thus haloperidol at 3 10 mg/kg produced significantly greater increases in HVA/DA and DOPAC/DA ratios in the striatum (ca. 300-350% of the control) than in the cerebral cortex (ca. 250% of the con trol) (Fig. 2B) . Neuroleptics are known to increase the DA metabolite level and enhance DA turnover in the striatum and cerebral cortex, which are innervated by DA neurons de rived from the substantia nigra and ventral tegmental area, respectively (1). This increase in DA turnover has been considered to be compensatory for the antagonism of the D2 receptor by neuroleptics. The blockade of D2 autoreceptors on the nerve terminals and soma/dendritic portions of DA neurons reportedly enhances the synthesis and synaptic release of DA and increases the firing of DA neurons (9) . In addition, the blockade of postsynaptic D2 receptors by neuroleptics has also been shown to increase the firing of DA neurons through discharge of the GABA mediated negative feedback mechanism (9) . In the present study, SM-9018 selectively increased the DOPAC and HVA levels in the cerebral cortex and striatum without sig nificantly affecting those in the other brain regions. The levels of NE, 5-HT and their metabolites were not sig nificantly changed by SM-9018 treatment.
The time course and dose response of the action of SM-9018 were relatively consistent with its D2 blocking activities in vari ous behavioral tests (6) , in that SM-9018 inhibited methamphetamine-induced hyperactivity, apomorphine induced climbing behavior and stereotypy with ED50 values of 2.2 to 5.8 mg/kg, p.o., thus suggesting that SM 9018 increased the DA metabolite levels through its D2 blocking activity.
SM-9018 is a potent antagonist of 5-HT2 receptors (6) . In addition, SM-9018 binds to 5-HTIA receptors with a relatively high affinity (7) . However, in this study, SM 9018 did not significantly change the levels of 5-HT or 5 HIAA in any brain regions examined. Our findings are consistent with previous findings (10, 11) that selective 5 HT2 antagonists (i.e., ritanserin and ICI-169,369) did not affect the 5-HT metabolism in the rat striatum, cortex and olfactory tubercle. In addition, SM-9018 may act as an an tagonist rather than agonist for 5-HT1A receptors since 5 HT1A receptor agonists (e.g., 8-OH-DPAT, tandospi rone), but not antagonists (e.g., pindolol), reportedly reduced the activity of 5-HT neurons and lowered the 5 HIAA level (5, 8, 12) . This is in agreement with the fact that SM-9018 did not induce any 5-HTIA receptor-related behaviors (e.g., fore-paw treading and flat body) as described previously (7). Our results, however, do not rule out a possibility that SM-9018 failed to interact with 5-HT1A receptors under our experimental conditions. SM-9018 was much weaker than haloperidol and chlor promazine in inducing catalepsy in rodents (6) . The ED50 values for catalepsy induction were about 20-50 times higher than those for D2 receptor antagonism. This sug gests that SM-9018 is an atypical neuroleptic character ized by the low incidence of EPS in humans. The D2 recep tor blockade in the cerebral cortex and/or limbic struc tures by neuroleptics has been implicated in their anti psychotic activities, whereas their action in the striatum has been suggested to be related to EPS (5) . In this study, SM-9018 increased the HVA/DA and DOPAC/DA ratios to a similar extent both in the cerebral cortex and stria tum. The dose-response curves for the increase in DA turnover by SM-9018 were also comparable between the two brain structures. In contrast, the typical neuroleptic haloperidol produced greater increases in DA turnover in the striatum than in the cerebral cortex. These findings in dicate that the action of SM-9018 in the striatum relative to that in the cerebral cortex is weaker than that of haloperidol. Our findings are consistent with previous reports (13) (14) (15) indicating that atypical neuroleptics (e.g., clozapine) exhibit similar potencies in increasing DA turnover both in the cortex and striatum, whereas typical neuroleptics (e.g., haloperidol) preferentially en hance the striatal DA turnover. Thus SM-9018, like other atypical neuroleptics, appeared to have a propensity to act on the mesocortical (vs. nigrostriatal) dopaminergic system as compared with typical neuroleptics. This may in part account for the lower incidence of EPS with SM 9018. Further studies are required to clarify the action mechanism of SM-9018.
